Nektar Therapeutics Stock Price and Value Analysis

Should you buy Nektar Therapeutics stock? (NasdaqGS:NKTR). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the NKTR Numbers

NKTR Price
(Nektar Therapeutics stock price per share)
[?] PE Ratio versus Sector 1241% higher than other Healthcare stocks
[?] PE Ratio versus Industry 370% higher than other Biotechnology stocks
[?] Cash Yield -3.43%
[?] Free Cash Flow Jitter 132%

Is Nektar Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Nektar Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NKTR Stock?

Does Nektar Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.